Back to News
Market Impact: 0.15
Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026
Source: GlobeNewswire
Healthcare & BiotechProduct Launches
Final efficacy results from the Phase 3 ORIGIN trial of TRUTAKNA (atacicept-vymj) in IgA nephropathy will be presented as a late-breaking oral session during the opening plenary at ASN 2026. The announcement signals prominent scientific visibility for the program but provides no efficacy, safety, regulatory, or financial data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
More News
- Your health insurance premiums may take a big jump in 2027 — here's why
- Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
- Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
- Meta wants you to build your own Muse gadget
- Rivian tops Q3 delivery expectations, reconfirms 2026 guidance
- iPhone 18 Pro Max can’t call or text on AT&T? Apple will replace it for free
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Research Workflows, Report Format Selection, and Interactive Synthesis
- Can ChatGPT Analyze a 10-K? A Verification Workflow